News

BioGenCell has completed the 6 Months follow-up

BioGenCell has completed the 6 Months follow-up in its first in human, phase I/II clinical trial in CLI patients (clinicaltrials.gov Identifier: NCT02805023). Results of this cohort of patients show that the treatment is safe and has therapeutic effects in both … Read More

Featured Post

BioGenCell has welcomed aboard Prof. Aaron Ciechanover

BioGenCell has welcomed aboard Prof. Aaron Ciechanover, the Nobel Prize Laureate (2004, chemistry). Prof. Ciechanover has joined BioGenCell’s Scientific Advisory Board and is renowned for his groundbreaking discoveries on the ubiquitin system and its major roles in homeostasis and in … Read More

Featured Post

BioGenCell has won an EU competitive grant this year of over one million Euros

BioGenCell has won an EU competitive grant this year of over one million Euros. This prestigious DGO6 grant was granted by the Belgium Authorities in the Wallonia region of Belgium and will allow us to embark upon the company’s product … Read More

Featured Post

BioGenCell has opened a fully owned subsidiary in Belgium

BioGenCell has opened a fully owned subsidiary in Belgium. The new company BioGenCell EU will continue in parallel with BioGenCell IL to advance its clinical studies, expansion of production and business development.

Featured Post

BioGenCell has welcomed aboard Mr. Marc Dechamps to its BioGenCell EU team

BioGenCell has welcomed aboard Mr. Marc Dechamps to its BioGenCell EU team, who will spearhead the activities in Europe. Formerly, Mr. Dechamps was the Executive Director of Specialty Care & Vaccines department at GSK, and subsequently, Head of the European … Read More

Featured Post

BioGenCell has received the approval of both the Israeli and Belgium Ministry of Health

BioGenCell has received the approval of both the Israeli Ministry of Health (MOH) and the Belgium Ministry of Health (FAMHP-Federal Agency for Medicines and Health Products) to continue its clinical trials on a larger scale as a double-blind placebo-controlled study.

Featured Post

BioGenCell has joint forces with Newcastle University

BioGenCell has joint forces with Newcastle University Institute of Cellular Medicine, Institute for Cell and Molecular Bioscience and North East England Stem Cell Institute and with the Laniado diabetes center in Israel for research on a new regenerative medicine. All … Read More

Featured Post

BioGenCell presented its innovative technology and insight to its clinical trial

BioGenCell presented its innovative technology and insight to its clinical trial at the annual, renowned conference, The 8th World Congress and Exposition on Cell & Stem Cell Research, March 20-22, 2017 Orlando, Florida, USA http://stemcell.conferenceseries.com/scientific-program. The conference focused on exploring … Read More

Featured Post

BioGenCell’s clinical study PI, Dr. Mark Niven

BioGenCell’s clinical study PI, Dr. Mark Niven, a worldwide leader in the field of diabetes and the Director of the Endocrine and Diabetes Unit, incorporating the Bildirici Center for Diabetes Care and Research at Laniado Hospital, Israel, gave a scientific … Read More

Featured Post

BioGenCell presented its promising results from its First In Human

BioGenCell presented its promising results from its First In Human (FIH) study in “no option’ CLI patients at the 45th Annual VEITH symposium on Vascular and Endovascular Issues, organized by the world-renowned Prof. Veith who is also on BioGenCell’s scientific … Read More

Featured Post